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Abstract
In blood malignancies, the balance of hematopoietic stem cell (HSC) self-renewal
and differentiation is disturbed such that HSCs produce abnormal cells with an increased
capacity to proliferate; however, the exact causes of this imbalance are not known.
SpeedyA1 (Spy1) is a positive cell cycle regulator known to enhance cellular proliferation
by direct binding and activation of Cyclin-dependent kinase (Cdk) Cdk2 and by
promoting degradation of the Cdk inhibitor (CKI) p27 Kip1. I demonstrate that Spy1
expression levels are elevated in early stem and progenitor cells during hematopoiesis,
but that Spy1 may also be implicated in later stages of myeloid differentiation. Spy1
protein was elevated in human bone marrow tumour samples and Spy1 knock-down in
HL-60 cells led to decreased cell growth as well as expression of leukemic stem cell
(LSC) markers. Together, these findings demonstrate a potential role for Spy1 in
regulating HSC fate and in the development of blood malignancies.
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INTRODUCTION
In Canada, there are approximately 90,000 people diagnosed with, or in remission
from, a variety of blood malignancies including leukemia and lymphoma1. Leukemia and
lymphoma are the most common cancers diagnosed in children and youth under the age
of twenty; these groups of cancers account for approximately one third and one fifth of
childhood cancers, respectively1-3. While advances in treatment have drastically improved
survival rates for some types of blood cancers4-11, there are still many for which a cure
has yet to be discovered4,12-13. Complicating the discovery of new treatments is the
enormous diversity among different types of blood cancers, each presenting with a
different genetic background not yet fully elucidated. Therefore, it is of utmost
importance to resolve the causes of blood cancers on a cellular and molecular level so that
better treatments can be implemented.
I.

Hematopoiesis: Blood Cell Development
The production and development of blood cells is a process known as

hematopoiesis. This process is arranged in a hierarchy such that all blood cells are derived
from a primitive hematopoietic stem cell (HSC) that is responsible for maintaining
homeostasis of the blood system (Figure 1)14-15. HSCs, like other stem cells, have the
unique ability to undergo asymmetric cellular division. Thus, they not only give rise to
more differentiated blood cells to produce all the many types of blood cells found in the
body, but they also generate more stem cells through self-renewal to maintain the pool of
adult stem cells.
Although HSCs were discovered over 50 years ago by McCulloch and Till16-18 and
first isolated over 20 years ago19, it was not until recently that HSCs were discovered to
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Figure 1. Hematopoietic Cell Development. Primitive HSCs give rise to all blood
cells of the body through a series of steps in which cells get progressively more
committed. LT-HSC, long-term repopulating HSC; ST-HSC, short-term repopulating
HSC; MPP, multipotent progenitor cell; CMP, common myeloid progenitor; CLP,
common lymphoid progenitor; MEP, megakaryocyte/erythroid progenitor; GMP,
granulocyte-macrophage progenitor. (from Larsson, J. And Karlsson, S. Oncogene
2005)14
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be a heterogeneous population of stem cells with differential reconstitution ability20-22,23.
In fact, different kinds of HSCs have now been characterized and isolated within the
human hematopoietic system22-29. The long-term repopulating HSC (LT-HSC) is thought
to be responsible for life-long maintenance of the adult stem cell pool22. LT-HSCs are
relatively rare, representing <0.01% of cells found in the adult bone marrow30-31. These
stem cells, when transplanted into irradiated mice, have been shown to be capable of
retaining engraftment potential indefinitely22. LT-HSCs are relatively inactive, dividing
infrequently to produce more rapidly proliferating short-term repopulating HSCs (STHSCs) which give rise to multipotent progenitors (MPPs) with a decreased ability for
self-renewal22,32. MPPs can differentiate into the common lymphoid progenitor (CLP)
and/or the common myeloid progenitor (CMP) and at this point in hematopoiesis, blood
cell development is restricted to the CLP or CMP lineage14-15.
Through a series of differentiation steps, CLPs will give rise to white blood cells
important for the functioning of the lymphatic system such as B-Lymphocytes, TLymphocytes, and Natural Killer cells14-15. CMPs give rise to erythrocytes,
megakaryocytes, granulocytes, and monocytes14-15. Erythrocytes (red blood cells) contain
hemoglobin and transport oxygen throughout the circulatory system and megakaryocytes
produce platelets which are important in the formation of blood clots33-34. Monocytes are
white blood cells that produce macrophages which are important in destroying bacteria3334

. Granulocytes are white blood cells important to the functioning of the human immune

system and include neutrophils, eosinophils, and basophils33-34.
The fate of HSCs is highly dependent on different growth factors present in the
microenvironment. While the roles of several growth factors and cytokines in
hematopoietic lineage decisions have been resolved, it is important to note that
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interleukin-3 (IL-3) and granulocyte-colony stimulating factor (G-CSF) are important in
specifying a myeloid fate30,35, whereas a lymphoid fate is largely controlled by the
presence of interleukin-7 (IL-7)30.
II.

Mammalian Hematopoietic Development
The hematopoietic system is one of the first mammalian tissue systems to form in

the developing embryo36-37. Primitive erythrocytes can be found in the blood islands of
the extra-embryonic yolk sac early on in embryonic development36-37. However,
definitive HSCs, capable of hematopoietic reconstitution upon engraftment in an adult
irradiated mouse, are first observed in the aorta-gonad-mesonephros (AGM)36-38. In
humans HSCs in the AGM are seen as early as embryonic day 27, indicating that the
AGM is the first site of hematopoiesis in the developing embryo37.
There are several developing organs involved in fetal hematopoiesis, including the
liver, spleen, thymus, and bone marrow, that can contribute to fetal blood cell production
after first being colonized by migrating blood cells34,36-37,39-40. Beginning as early as
embryonic week 5 in humans the liver plays a distinctive role in fetal hematopoiesis as it
supports proliferation and differentiation of the colonizing progenitor cells37.
Nonetheless, it is not until later in embryonic development that the human fetal liver
produces definitive HSCs that express the stem cell marker CD34 and have the capacity
to undergo hematopoiesis in vitro37,39. At this point, the liver is the primary organ
responsible for human fetal hematopoiesis37.
The bone marrow is the last tissue important for hematopoietic development that
is established in utero. The bone marrow microenvironment begins to form around 10
weeks during human embryonic development and primitive myeloid and erythroid cells
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can be found in the developing marrow as early as week 1137. However, HSCs capable of
hematopoietic reconstitution are not observed in the marrow until right before birth37. At
this time, blood development is diminished in the yolk sac and occurs only to a limited
extent in the liver37. This sequence of events has been shown to be very similar to that of
hematopoietic development in mice36.
The bone marrow will sustain hematopoiesis on a long-term basis for the
remainder of the mammalian lifespan. However, other organs also serve important
hematopoietic functions in the adult mammal. First, the spleen aids in red blood cell
turnover as it is responsible for the destruction of damaged red blood cells; it also
contributes to white blood cell synthesis40. In addition, the thymus plays a role in adult
lymphocyte maturation40. Moreover, the adult liver is also involved in the turnover of red
blood cells40 and has been found to contain small populations of adult HSCs41. HSCs can
also be found in very small numbers in the circulating peripheral blood. An understanding
of the role each secondary hematopoietic tissue plays in hematopoiesis is important as
both fetal and adult tissues were examined in this work.
III.

HSC Quiescence
The majority of adult HSCs, like other adult stem cells, remain in a relatively

inactive state with low turnover referred to as quiescence32,42-43. HSC quiescence is
largely controlled by cell cycle inhibitors at G1 phase of the cell cycle including p21, p27,
and p57 as well as by the tumour suppressor protein p5344-47. The infrequent division of
HSCs acts as a protective mechanism to limit DNA damage and to prevent premature
proliferative exhaustion of the stem cell pool32,42-43. However, as previously mentioned,
HSCs do enter the cell cycle occasionally to give rise to ST-HSCs that will support the
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continuous production of many types of blood cells32,42-43. Furthermore, under times of
physiological stress on the hematopoietic system such as injury or severe blood loss, adult
HSCs are capable of exiting quiescence and rapidly proliferating to repopulate the
hematopoietic system42. Thus, HSCs are relatively quiescent under homeostatic
conditions, but retain the ability to rapidly self-renew when necessary.
IV.

Hematopoietic Malignancies: Subtypes
Leukemia is primarily a disease of the hematopoietic system affecting organs such

as the bone marrow and circulating blood. There are many different subtypes of leukemia
that are classified based on the type of blood cell that is affected. Lymphoblastic or
lymphocytic leukemia initiates in a marrow cell that is a precursor of a lymphocyte48.
Myelogenous or myelocytic leukemia initiates in a marrow cell that is destined to become
a red blood cell, platelet, or a type of white blood cell other than a lymphocyte48.
Leukemia can be further classified into several subtypes based on how quickly the disease
develops and on the maturation stage of the cells as determined by staining and pathology
analysis48. Chronic leukemia takes months, sometimes even years, to develop and is most
common in adults3,48. On the other hand, acute leukemia, the most common form of
leukemia in children3, has a rapid onset and can progress much more quickly48.
Similar to lymphocytic leukemia, lymphomas involve abnormally proliferating
lymphocytes. Unlike leukemia however, lymphoma results in the formation of masses of
tumourigenic cells in the lymph nodes. The cancer can also spread to the liver, spleen,
and other parts of the lymphatic and immune system; metastases to the lungs, bone, and
central nervous system are also known to occur3.
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Finally, a blood disorder known as myeloma also exists. Multiple myeloma is the
second most common hematological malignancy and accounts for approximately 1% of
all cancers49. This disease primarily develops in B lymphocytes as they mature in the
marrow to become plasma cells49. Cancerous plasma cells grow very rapidly and, in
doing so, they prevent normal production of healthy blood cells and platelets; the end
result is the formation of tumours in the marrow of the bones affected. Myeloma cells can
invade and weaken the bones causing what are known as osteolytic lesions or bone
lesions49. A plasmacytoma refers to a patient with a bone lesion or tumour in only one
site, whereas, multiple myeloma refers to a patient with tumours in the marrow of
multiple bones49.

V.

Blood Malignancies: Involvement of Cell Cycle Proteins
Although there are several different types of blood cancer, each affecting different

kinds of blood cells at different stages of hematopoietic development, the common
hallmark of blood cancers is an abnormal proliferation of specific kinds of blood cells.
While the molecular mechanisms driving this abnormal proliferation have not been fully
elucidated, several cell cycle proteins have been found to be implicated in different blood
malignancies.
The mammalian cell cycle is largely regulated by a family of protein kinases
called Cyclin dependent kinases (Cdks) that, when bound to Cyclin proteins, can promote
progression through the cell cycle. In addition to cyclin binding, Cdks are activated posttranslationally via phosphorylation by Cdk activating kinase (CAK) and removal of
inhibitory phosphates by the Cdc25 phosphatases. Cdks are also negatively regulated by
Cdk inhibitors (CKIs), such as the Cip/Kip family of inhibitors which bind to Cdk-Cyclin
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complexes and interfere with the proper folding of the catalytic cleft, thereby, rendering
the complex inactive. The Cip/Kip family includes p27Kip1, p21Cip1 and p57Kip2.
Several blood malignancies have been found to display elevated Cdk levels and
low levels of CKIs have been associated with poor prognosis in patients50-52. For example,
leukemia patients with low levels of p27 have presented with a worse prognosis51 and
aberrant regulation of p21 has also been demonstrated in many human leukemias44.
Furthermore, an increase in Cdk2 activity has been observed in both lymphoid and
myeloid derived leukemias as well as in some lymphomas50,52. This increase has partly
been attributed to the abnormal localization of p27 in the cytoplasm where it cannot
inhibit activity of Cdk252.

VI.

Cancer Stem Cell Hypothesis & Leukemic Stem Cells
A population of cells known to drive tumour growth has been shown to exist in

many cancers15,53-57. These cells, termed cancer stem cells (CSCs) possess similar
characteristics of normal stem cells in that they can propagate themselves and also
differentiate; thereby, they can not only sustain growth of the cancer, but can also give
rise to the many differentiated cell types found within a heterogeneous tumour15,58.
The existence of CSCs in blood malignancies was originally hypothesized based
on the observation that only a very small percentage of human leukemia cells had
clonogenic properties59-60. However, the first conclusive evidence for the existence of
CSCs in leukemia came from the identification of a rare population of human acute
myeloid leukemia (AML) cells that could generate leukemias representative to the human
disease in xenograft transplants53,61-62. These CSCs, called leukemic stem cells (LSCs),
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were later shown to continuously generate leukemias in murine serial transplantation
experiments, indicating that they possessed an indefinite potential to self-renew58,63.
Although the discovery of LSCs in AML has prompted much research in the area,
the origin of LSCs has not yet been completely resolved. LSCs may result from the
transformation of normal HSCs or they may arise from mutations or epigenetic changes
in more committed progenitor cells allowing for enhanced self-renewal64-65. Interestingly,
there has been evidence to support that AML is organized in a hierarchy with distinct
classes of LSCs with differential long term repopulating (self-renewal) potential similar
to that of HSCs53,58. Resolving the ambiguity surrounding the origin of the LSC will aid in
the determination of specific molecular markers that are differentially expressed in
normal and leukemic stem cells. This is a necessary step in targeting LSCs to eradicate
this population therapeutically. To date, a few cell surface markers have been found to be
commonly deregulated in leukemias and researchers are beginning to exploit these for
drug design and clinical trials66-70. In AML the markers CLL-1 and CD33 have been
identified as potential therapeutic targets for the eradication of LSC populations67-70.
Although possessing the ability to rapidly self-renew, many LSCs have been
shown to be quiescent, similar to LT-HSCs58,64,71-72. This low cycling state provides the
same protective advantages to LSCs as it does to normal HSCs, limiting DNA damage
and preventing exhaustion of the LSC population72. LSCs are also known to contain an
abundance of ATP-Binding Cassette Transporters (ABC Transporters)73. ABCtransporters are proteins known to efficiently pump chemotherapeutics out of the cell,
contributing to drug resistance. The presence of ABC-transporters and the relatively low
cycling rate of LSCs makes them highly resistant to conventional therapies, especially
those involving chemotherapeutic drugs55,58,64,71-73. Thus, LSCs often persist in the patient
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post-treatment and can initiate disease relapse (Figure 2)55,64,71,73. It is extremely
important to uncover novel ways to target the LSC population in different blood
malignancies to successfully induce disease remission. This requires resolving the
origin(s) and mechanisms behind the development of LSCs.

VII.

Spy1
SpeedyA1 (Spy1) was initially identified by two independent groups. Ferby and

colleagues demonstrated that a novel protein, p33-RINGO (Rapid Inducer of G2-M
Progression in Oocytes) was sufficient to initiate oocyte maturation in Xenopus and that
depletion of this protein inhibited progesterone-induced oocyte maturation74. Similarly,
Lenormand and colleagues also discovered a novel protein, Spy1, that could induce
Xenopus oocyte maturation and that this was dependent on activation of the MAPK
pathway75.
To date, Spy1 is known to be expressed in a variety of human tissues and cell
lines76; of particular interest to this study are the thymus and the liver. Spy1 was also
found to be a nuclear protein and to be expressed in a cell cycle dependent manner,
peaking in G1/S phase76. Although Spy1 has no sequence homology to the Cyclin
proteins, it has been found to be capable of binding and activating both the G2/M Cdk,
Cdk1, and the G1/S Cdk, Cdk274-77. Interestingly, Spy1 can activate Cdk1 and Cdk2 in
the absence of phosphorylation of the respective Cdks on Thr-161 and Thr-160; a
modification normally required for Cdk kinase activity77. In addition, Spy1-Cdk2
complexes have been found to have broader substrate specificity than other Cyclin-Cdk2
complexes, suggesting that Spy1 may alter the substrate specificity of Cdk278. Taken
together, the novel activation and altered substrate specificity of Cdk2 by Spy1 may result
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Figure 2. LSC Hypothesis. (A) The LSC hypothesis predicts that the leukemic blast cell
population is maintained by a small subset of tumourigenic cells with stem cell properties.
LSCs can self-renew and differentiate to maintain the heterogeneous tumour. (B) Current
treatments do not target LSCs so they persist and can initiate relapse. Novel treatment
designs that target LSCs may help eliminate the entire malignancy. (from Guzman, M.L.
and Jordan,C.T. Cancer Control 2004)55
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in aberrant proliferation at times when it may be inappropriate; this represents one way in
which Spy1 could contribute to tumourigenesis.
Additionally, Spy1 is capable of overriding normal cellular responses to stress
such as apoptosis, senescence, and DNA damage response pathways79. It is known that
endogenous Spy1 levels increase in cells following treatment with DNA damaging agents
and that the overexpression of Spy1 enhances cell survival in the presence of such agents
by preventing apoptosis and interfering with repair pathways79-81. Specifically, the
overexpression of Spy1 prevents cells from efficiently activating both G1/S and G2/M
phase checkpoints following exposure to ultraviolet radiation and the activation of DNA
damage response pathways increases in the absence of Spy179,81. Moreover, Spy1-Cdk
complexes demonstrate decreased sensitivity to inhibition by the cell cycle inhibitor,
p21Cip1 and Spy1 has been shown to be capable of overriding the p27Kip1-mediated
checkpoint at G1/S phase of the cell cycle77,82-83. Collectively, these findings have
demonstrated that Spy1 can also contribute to tumourigenesis by promoting cell cycle
progression even in the presence of cellular stressors.
Recent data from our lab have demonstrated a role for Spy1 in maintaining
stemness in the breast and the brain84. In addition, Spy1 is known to be elevated in many
human cancers and it has been recently reported as important in human non-hodgkin’s
lymphomas85. Hang and colleagues found that Spy1 protein was highly expressed in a
variety of different types of human non-hodgkin’s lymphoma samples and that this
expression was correlated with that of proliferation markers85. Importantly, they found
that patients with high levels of Spy1 protein had a worse prognosis and decreased overall
survival compared to patients with lower levels of Spy1 protein85.
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The goals of this study were to explore the involvement of Spy1 in normal
hematopoietic cell development and to determine its role in human blood malignancies.
Initially, I sought to examine the expression of Spy1 in different hematopoietic tissues
and to establish a role for Spy1 in hematopoietic fate decisions in vitro. Secondly, I aimed
to discover whether Spy1 may be implicated in hematopoietic malignancies, particularly
those known to contain LSC populations.

Objective 1: Determine a role for Spy1 in hematopoietic stem cell fate. EML cells were
utilized as a model system of hematopoietic development. These are murine bone marrow
cells representative of MPP populations that are capable of responding to differentiation
stimuli to generate differentiated blood cells of the erythroid, myeloid, and lymphoid
lineages30,86. Spy1 expression was examined during the myeloid differentiation of EMLs
in vitro.

Objective 2: Study the role of Spy1 in the development of hematopoietic malignancies.
HL-60 cells were used as a representative case of acute myeloid leukemia as Spy1 is
known to be highly expressed in this line. Short hairpin RNA (shRNA)-mediated knockdown of Spy1 was performed and growth assays were used to study the effects of Spy1
depletion on leukemic cell growth. Gene expression levels of known LSC markers in
AML were also studied following shRNA-mediated depletion of Spy1.

Moreover,

analysis of Spy1 protein levels in human bone marrow tumours was also performed.

Collectively, this study aims to broaden the understanding of novel cell cycle regulators
during normal hematopoiesis and in various blood malignancies, particularly AML. The
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findings of this study have identified Spy1 as important in regulating HSCs and have
suggested a potential role for Spy1 in LSC populations. Overall, the outcomes of this
study may have important implications in the treatment of blood malignancies.
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MATERIALS AND METHODS
I.

Tissue Microarray Analysis
Paraffin-embedded Tissue Microarray slides (US BioMax) were first baked at

60˚C to remove paraffin. Immersion in xylene for 10 minutes, followed by subsequent
immersion in 100% ethanol, 95% ethanol, and 70% ethanol for 5 minutes each was then
performed to rehydrate the slide. After being washed in 1X PBS for 5 minutes, slides
were immersed in sodium citrate buffer (pH 6.0) at 95ºC for approximately 15 minutes
for antigen retrieval. Slides were then stained with different antibodies. Specifically, a
blocking antibody (normal goat serum; Cayman Chemical 10006577) was applied to the
slides at room temperature for 20 minutes followed by application of anti-Spy1 antibody
at a dilution of 1:100 (Novus Biologicals NB100-2521) for 60 minutes also at room
temperature. Slides were washed twice for 5 minutes in 1X PBS prior to application of a
fluorescence-conjugated secondary antibody (Alexa488-goat anti-Rabbit IgG; Invitrogen
A11008) at a dilution of 1:1300 for 20 minutes at room temperature in the dark. Slides
were again washed in 1X PBS before application of TOTO-3 nuclear stain (1:1300;
Molecular Probes T-3600) for 20 minutes in the dark. After a final wash in 1X PBS for 5
minutes, slides were immersed subsequently in 70%, 95%, and 100% ethanol for 5
minutes each, followed by immersion in xylene for 8 minutes. Slides were mounted to
coverslips and ScanArray Express software (Perkin Elmer Inc.) was used to detect and
quantify fluorescence. Data were normalized to the nuclear stain, TOTO-3. To control for
non-specific signals, slides were compared to previously established slides stained with
secondary antibody alone.
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II.

Murine Hematopoietic Tissue Extraction
Balb-C mice were humanely sacrificed at post-natal day 7 and every week

thereafter for 6 weeks for the extraction of tissues. All dissection tools were sterilized
prior to use. Incisions were made on the ventral surface of each mouse beginning at the
posterior end and moving anteriorly up the centre of the mouse to expose the body cavity
and the internal organs. Samples of the liver, spleen, and thymus were cut, placed in an
eppendorf tube and flash frozen in liquid nitrogen prior to storage. Peripheral blood was
extracted using a syringe and needle. Bone marrow samples were obtained by flushing the
bones of the hind limbs with 1X PBS; bone marrow from both left and right femurs and
tibias were pooled. Red blood cells were removed by incubation with red blood cell lysis
buffer (Sigma R7757) for up to 5 minutes on ice followed by centrifugation at 1200 rpm
and 4ºC for 5 minutes. All samples were flash frozen in liquid nitrogen prior to storage in
a -80ºC freezer. Three samples of each tissue were taken from one mouse for each time
point.

III.

Protein Extraction
Murine tissue samples were lysed and homogenized using a Sonic 60

Dismembrator (Fisher Scientific FM2602) followed by centrifugation for 20 minutes at
10,000 rpm and 4ºC to remove any fat or undesired tissues. For lysates in which fat was
still present, a second centrifugation was necessary. Lysis buffer was composed of 0.1%
Nonidet P-40, 50 mM Tris-HCl pH 7.4, 0.25% Deoxycholate acid, 1 mM EGTA pH 8.0,
0.2% SDS, and 150 mM NaCl. The following protease inhibitors were added: PMSF (10
µL/mL); Leupeptin (1 µL/mL); and Aprotinin (0.5 µL/mL). Protein lysates were stored at
-80ºC.
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IV.

Immunoblotting
Protein concentrations of lysates were determined using the Micro-BCA protein

assay kit (Thermo Scientific). Briefly, protein lysates were mixed with a working reagent
in a 1:1 ratio and allowed to incubate at 60ºC for 60 minutes prior to analysis of
absorbance at 562 nm in a spectrophotometer (Biomate 5, Thermo Electron Corporation
BIO 145108). All protein concentrations were corrected to the reading of lysis buffer. A
total of 50 to 100 µg of lysate was prepared in 4X sample buffer (10% glycerol, 62.5 mM
Tris-HCl pH 6.8, 2% SDS, 0.01 mg/mL bromophenol blue, and 2% β-mercaptoethanol),
boiled for 5 minutes, and run on a 10% SDS gel for 3 hours at 120 volts. Gels were
transferred onto PVDF membrane (Millipore IPVH00010) for 2 hours at 30 Volts and
membranes were subsequently blocked in 1% milk for a minimum of 45 minutes.
Membranes were blotted with either anti-Spy1 antibody (Novus Biologicals NB1002521) or anti-Spy1 antibody (AMICUS Biotech) overnight at 4ºC for detection of Spy1 or
with anti-actin monoclonal antibody (Chemicon Intl. MAB1501R) for 1 hour at room
temperature for detection of a loading control protein. Secondary antibodies were either
anti-rabbit IgG (Sigma A0545) or anti-goat (Santa Cruz sc-2020) for Spy1 and antimouse IgG (Sigma A9917) for actin. All secondary antibodies were applied at room
temperature for 1 hour. Membranes were washed in between primary and secondary
antibody applications with TBS-Tween. Protein was visualised and densitometry was
analyzed using FluorChem HD2 imaging software (Alpha Innotech). Only results
obtained with the Spy1 antibody from Novus Biologicals are shown.
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V.

Cell Culture
EML cells were purchased from American Type Culture Collection (CRL-11691)

and cultured in Iscove’s Modified Dulbecco’s Medium (IMDM; ATCC 30-2005)
supplemented with 20% heat-inactivated fetal bovine serum (hiFBS; Invitrogen 906532),
1% penicillin/streptomycin solution (P/S; GIBCO 991805), and 50 ng/mL murine stem
cell factor (SCF; MyBioSource MBS400071). EML cells were maintained at a cell
density of 2.0 x 105 cells/mL and 2 x 106 cells/mL and passaged every 2 to 3 days. HL-60
cells were a kind gift of Dr. Michael Boffa (University of Windsor, Biochemistry
Department) and were cultured in IMDM supplemented with 20% FBS and 1% P/S. All
cells were maintained in a 37°C humidified incubator set to 5% CO2.

VI.

Differentiation of EML Cells
To induce differentiation of EML cells into myeloid progenitor cells, 1 x 105

cells/mL were seeded in either 12 or 6 well plates. Differentiation media consisted of
complete growth media (IMDM with 20% hiFBS, 1% P/S, 50 ng/mL SCF) with the
addition of 10 ng/mL murine interleukin-3 (IL-3; Peprotech 213-13), and 10-5 all-trans
retinoic acid (atRA; Sigma R2625). Control cells were grown in the absence of IL-3 and
atRA. All plates containing atRA were stored in the dark. Cells were collected by
centrifugation at 0, 24, 48, and 72 hours after the addition of differentiation media.
Myeloid progenitor cells generated by 72 hours of growth in media containing IL3 and atRA were maintained in IMDM supplemented with 20% hiFBS, 1% P/S, and 10
ng/mL murine granulocyte macrophage-colony stimulating factor (GM-CSF; Peprotech
315-03). After 5 to 7 days of incubation with GM-CSF, myeloid progenitor cells were
selected. To induce terminal differentiation, GM-CSF-dependent myeloid progenitor cells
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were seeded at a density of 1 x 105 cells/mL in either 12 or 6 well plates in complete
growth media containing 10 ng/mL murine GM-CSF and 10-5 M atRA. Control myeloid
progenitor cells were grown in the absence of atRA. All plates with media containing
atRA were stored in the dark. Cells were collected by centrifugation at 0, 24, 48, and 72
hours after the addition of atRA.

VII.

EML Immunomagnetic Cell Sorting
To obtain a CD34+ population of cells, EML cells were sorted using Dynabeads

M-450 Epoxy (Invitrogen 140.11) and an EasySep Magnet (Stem Cell Technologies
18000) according to the manufacturer’s protocol. Briefly, magnetic beads were
conjugated to anti-CD34 antibody (Santa Cruz IC0115) by incubation for 16 to 24 hours
on a mutarotator at room temperature (5 µg anti-CD34 per 25 µL of Dynabeads). 25 µL
of CD34-conjugated magnetic beads and 25 µL buffer (0.1% BSA in 1X PBS) were
allowed to incubate with 2.5 x 106 cells at 4ºC for 20 minutes with gentle rotation on a
mutarotator. This ratio was scaled up or down depending on the starting cell number.
Following this, a magnetic field was applied for 1 minute in the EasySep Magnet causing
CD34+ cells to be pulled to the inner walls of a test tube so that CD34- cells could easily
be obtained by removal of the buffer. Several 2 to 3 minute washes with 0.1% BSA buffer
removed the CD34+ cells. CD34- and CD34+ cells were plated in 6 well tissue culture
plates for approximately 1 week prior to collection, along with a heterogeneous
population of EML cells, for further analysis.
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VIII. HL-60 Lenti-viral Infections
All HL-60 cell infections were performed in either 96 or 24 well plates. 5.0 x 104
cells/well were seeded for infections in 96 well plates and 1.0 x 105 cells/well were
seeded for infections in 24 well plates. For all infections, HL-60 cells were seeded in
serum-free and antibiotic-free IMDM containing 1 µg/mL polybrene (SantaCruz sc134220). Cells were allowed to incubate with polybrene-containing media for
approximately 20 minutes before the addition of virus. Cells were infected with a vector
carrying shRNA against Spy1 (pLKO-shSpy1) and control cells were infected with
pLKO-shScrambled (pLKO). Lenti-virus was used at a titre of 107 transducing units
(TU)/mL and a multiplicity of infection (MOI) of 2 was used for all infections. Virus was
removed by centrifugation and replaced with complete growth media approximately 20
hours after the addition of virus. Cells were allowed a 24 to 48 hour recovery period prior
to the addition of puromycin (Sigma P9620) at a final concentration of 2 µg/mL to select
for successfully infected cells. Puromycin selection was performed for a minimum of 72
hours before any subsequent assays. Non-infected control cells that were subjected to the
same procedure were included in all cell infections. Quantitative real-time polymerase
chain reaction (qRT-PCR) for expression of the human Spy1 gene was performed to
quantify infection efficiency.

IX.

HL-60 Cell Proliferation Assays
Upon successful selection in puromycin, cells expressing pLKO and pLKO-

shSpy1 were counted using Trypan Blue exclusion and cell counts performed using a
BioRad TC10 Automated Cell Counter. 100,000 cells were seeded in 6 well plates in
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complete growth media and cell counts were performed in triplicate every 24 hours for 3
days using Trypan Blue exclusion. Wildtype HL-60 cells were also included.

X.

HL-60 Cancer Stem Cell Marker Analysis
After successful selection in puromycin, cells expressing pLKO and pLKO-

shSpy1 were collected along with wild-type HL-60 cells for qRT-PCR analysis of
leukemic stem cell markers commonly used as diagnostic markers in acute myelogenous
leukemias. Genes examined were human CD33 and CLL-1. mRNA levels of each gene in
cells exhibiting Spy1 knock-down were compared to levels in pLKO-infected control
cells.

XI.

HL-60 Cell Differentiation
To induce granulocytic differentiation, 1 x 105 cells were seeded in 6 well plates.

Differentiation medium consisted of complete growth media with the addition of atRA at
a final concentration of 1 µM. Additional cells were also seeded in media containing
0.1% ethanol to serve as vehicle controls. Cells were allowed to differentiate over a
period of 5 days; media was changed every 48 hours and cells were grown in the dark.
Vehicle control and differentiated cells were collected 3 days and 5 days after the addition
of atRA for further analysis.

XII.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Total RNA was extracted from cell pellets using an RNeasy Extraction Kit

(Qiagen 74134). Briefly, samples were lysed and homogenized prior to the removal of
genomic DNA. Ethanol was used to enhance binding of RNA to an RNeasy spin column
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and a series of wash steps were performed before elution of RNA using RNase-free
water. RNA concentrations and quality were assessed on a NanoDrop Spectrophotometer
(ND-1000 software version 3.3.0 Thermo Scientific). RNA was reverse transcribed using
Superscript II reverse transcriptase (Invitrogen 100004925), 0.5 µg Oligo dT’s (Eurofin)
and 0.5 µg random nanomers (Thermo Scientific SO142). qRT-PCR was performed using
Fast SYBR green detection (Applied Biosystems 4385616) on an ABI Viia7 thermocycler
(Applied Biosystems 278880504). All qRT-PCR reactions were performed for 55 cycles
and the stages were as follows: denaturation of cDNA was performed at 95ºC for 1
minute; annealing of primers to single stranded DNA occurred at 60ºC for 20 minutes;
elongation occurred at 72ºC for 30 seconds. All gene-specific primers were used at a
concentration of 5 µM with the exception of murine Spy1 and murine Sca-1 primers
which were used at a concentration of 6 µM. Primer pairs are listed in Table 1. All data
were normalized to GAPDH as an internal control.

XIII. qRT-PCR Calculations
All qRT-PCR reactions were analyzed using Viia7 software version 1.1.5 to
generate Ct values. Briefly, the Ct of all target genes is balanced to that of the internal
control, GAPDH, such that ΔCt values are calculated (example: ΔCtSpy1 48hr = CtSpy1 48hr –
CtGAPDH 48hr). The sample to which all other samples will be compared is then set to zero
to generate ΔΔCt values; in this case, wildtype cells, pLKO control cells, or 0hr time
points for differentiation experiments were set to zero (example: ΔΔCtSpy1 48hr = ΔCtSpy1
48hr –

ΔCtSpy1 0hr). The relative quantification (RQ) value is then calculated by taking 2-ΔΔCt

(example: RQSpy1

48hr

= 2-ΔΔCtSpy1

48hr).

All data represents log10 relative quantification.

Error bars represent the standard error of the mean ΔCt value.
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Table 1. Murine qRT-PCR Primer Pairs
Murine
Gene
GAPDH
Spy1
c-kit
Sca-1
CD34
Mac-1
Gr-1
C/EBPε

Forward Primer (5’-3’)
GATGCCCCCATGTTTGTGAT
GCTTTAGGGAAAAACTGGAGA
AAA
GGGCAAGAGTTCCGCCTTCTT
CTCTGAGGATGGACACTTCT
GAGAATTCTGGAATCCGAGAA
GTGAGGT
GCCAATGCAACAGGTGCATAT
TGGACTCTCACAGAAGCAAAG
GACCTACTATGAGTGCGAGCC
T

Reverse Primer (5’-3’)
GTGGTCATGAGCCCTTCCA
AATGGCCATGACCTCTTCACA
GCTGCGACCACAAAGCC
GGTCTGCAGGAGGACTGAGC
ACTCTAGAACCCAGCCTTTCTCC
TGTAG
CACACATCGGTGGCTGGTAG
GCAGAGGTCTTCCTTCCAACA
ACACCCTTGATGAGGGTAGCAG

Table 2. Human qRT-PCR Primer Pairs
Human
Gene
GAPDH
Spy1
CD33
CLL-1
Mac-1

Forward Primer (5’-3’)
GCACCGTCAAGGCTGAGAA
C
TTGTGAGGAGGTTATGGCCA
TT
AAGTACAGGAGGAGACTCA
GG
GTGATGATGTCCAAACATGG
C
AGTTGCCGAATTGCATCGA

Reverse Primer (5’-3’)
GGATCTCGCTCCTGGAAGATG
GCAGCTGAACTTCATCTCTGTTGT
AG
GTGATTATGAGCACCGAGG
GATTGATGCCTCATGCCTCC
GGCGTTCCCACCAGAGAGA
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XIV. Statistical Analysis
All statistical analyses for qRT-PCR data was performed with the use of a
Student’s paired t-test. Data were only taken as significant if the p-value was less than
0.05. For statistical analysis on the tissue microarray of human multiple myeloma samples
(TMA T293) a Student’s paired t-test was performed in Statistica software.
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RESULTS
I.

Spy1 Protein is Expressed in Mammalian Sites of Hematopoiesis
To analyse protein expression of Spy1 in tissues known to be implicated in blood

cell production and maturation, tissue microarray analysis was performed. Tissue samples
present on the microarray represent those of a human fetus at age 5 months gestation.
Tissues were stained with anti-Spy1 and anti-rabbit-Alexa 488 antibodies as well as
TOTO-3 nuclear control stain in order to quantify Spy1 protein levels. Although several
human tissues were analysed, those of interest to blood cell development are the thymus,
liver, spleen, and bone. Results indicate that Spy1 is expressed at the protein level in the
thymus, liver, spleen, and bone and that this expression is moderate in comparison to
other tissues represented on the microarray (Figure 3A). Interestingly, of the
hematopoietic tissues examined, Spy1 was expressed to the greatest extent in the liver and
the bone.
Further analysis on liver, spleen, and thymus samples from Balb/C mice at postnatal age 7 and 21 days was performed using SDS-PAGE and immunoblotting (Figure
3B). Results were quantified using densitometry and Spy1 protein levels were analyzed
relative to an internal control protein, actin. Results indicate that Spy1 protein is
expressed in all the murine hematopoietic tissues sampled thus far. Remaining consistent
with the tissue microarray data, Spy1 protein was expressed to the highest extent in the
liver. Furthermore, levels of Spy1 protein showed, at minimum, a 2 fold decrease at each
site by day 21. Overall, these results show that Spy1 is expressed in mammalian tissues
important for hematopoietic development.
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Figure 3. Spy1 protein is expressed in mammalian hematopoietic tissues. (A) Spy1
protein levels in human fetal samples as measured by tissue microarray analysis. Values
are presented as relative to the nuclear control TOTO-3. Error bars represent standard
error of the mean of at least 3 separate samples for each tissue. Hematopoietic tissues are
highlighted in red boxes. (B) Levels of Spy1 protein in Balb/C spleen, liver, and thymus
tissue samples extracted at post-natal days 7 and 21. Densitometry analysis depicts the
ratio of Spy1 protein relative to loading control (β-Actin). Error bars represent standard
error of the mean of 3 protein lysates from each tissue.
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II.

Spy1 Expression Decreases During EML Myeloid Differentiation
The multipotent murine bone marrow cell line, EML, was used as a model for

hematopoietic myeloid differentiation. EML cells were stimulated to differentiate down
the myeloid cell lineage to become more committed early progenitor cells capable of
producing many myeloid cell types (Figure 4A). Specifically, EML cells were given
murine IL-3 and atRA over a time period of 3 days. Control cells were grown in the
absence of IL-3 and atRA. mRNA expression of Spy1 relative to EML control cells was
evaluated every 24 hours using qRT-PCR. Results indicate that both of the stem cell
markers c-kit and Sca-1 significantly decrease over time (Figure 4B & 4C) while the
myeloid specific differentiation markers, Mac-1 and Gr-1, both increase over time (Figure
4D & 4E). Collectively, these results indicate that the EML cells were successfully
undergoing myeloid differentiation. Furthermore, it was demonstrated that Spy1 mRNA
consistently decreases as EML cells are forced to differentiate into myeloid progenitor
cells; at least a 3-fold decrease was observed at all time points (Figure 4F). These results
were found to be statistically significant.

III.

Spy1 Expression is Elevated in CD34+ EML Cells
It has previously been shown that EML cells are a heterogeneous population of

multipotent blood cells30,86. Immunomagnetic sorting using anti-CD34 antibody was
performed to isolate the CD34+ and CD34- populations of EML cells; these populations
have been shown previously to possess stem-like characteristics26,52,86-87. qRT-PCR
analysis of CD34 mRNA levels shows successful sorting of CD34+ and CD34- cells
(Figure 5A). qRT-PCR analysis of Spy1 mRNA levels within each population compared
to a heterogeneous population was also performed (Figure 5B). Although these data
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Figure 4. Spy1 expression decreases during EML myeloid differentiation. (A) A schematic representation of EML cell differentiation. Differentiation steps (arrows) and
growth factors used are marked in red. (B-F) qRT-PCR was used to analyze mRNA levels
of stem cell markers: c-kit (B) and Sca-1(C) as well as myeloid specific differentiation
markers: Mac-1 (D) and Gr-1(E), and Spy1 (F). All data are normalized to GAPDH and are
expressed as relative quantification (RQ) on a logarithmic scale (log 10). Error bars represent standard error of the mean of three independent experiments each run in triplicate.
Statistical analysis was performed using a Student’s paired t-test (*p<0.001, **p<0.002,
***p<0.005, ****p<0.05)
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represent only two independent experiments, these preliminary results indicate that Spy1
is elevated in the CD34+ population; this is an approximately 50 fold increase over the
CD34- EML cell population. Taken together, the results presented in Figures 4 and 5
demonstrate correlative expression of Spy1 in early stem and MPP cells in the
hematopoietic system.

IV.

Spy1 Expression Increases During EML Terminal Myeloid Differentiation
EML cells that were successfully differentiated into myeloid progenitor cells were

further stimulated with murine GM-CSF and atRA to induce differentiation into terminal
cells of the granulocyte and monocyte lineages (Figure 6A). It is important to note that
EML-derived myeloid progenitors are absolutely dependent on GM-CSF for growth;
therefore, control cells were grown in the absence of atRA and the presence of GM-CSF.
Gene expression of Spy1, c-kit, and the myeloid specific differentiation markers, Mac-1
and C/EBPε, was analyzed using qRT-PCR every 24 hours for a period of 72 hours.
Results show that myeloid progenitor cells were successfully differentiating into terminal
myeloid cells as indicated by the decrease in c-kit expression (Figure 6B) and the increase
in both Mac-1 (Figure 6C) and C/EBPε (Figure 6D) expression. However, the control
cells showed a slight increase in Mac-1 and C/EBPε, indicating spontaneous
differentiation potentially as a result of GM-CSF. Although results were inconsistent with
regards to Spy1 expression levels between 4 independent experiments, results do suggest
that Spy1 may be increased at the gene expression level during these later stages of
differentiation (Figure 6E).
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Figure 5. Spy1 expression is elevated in CD34 + EML cell populations. Relative
mRNA levels of CD34 (A) or Spy1 (B) were assessed by qRT-PCR in heterogenous EML
populations, CD34 enriched populations (CD34 +), and the CD34 negative populations
(CD34-). Data are normalizedto GAPDH and arepresented as the relative quantification
(RQ) depicted on a logarithmic scale (log10). Error bars represent the standard error of the
mean of two independent sorts each run in triplicate qRT-PCR reactions.
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Figure 6. Spy1 mRNA levels increase during EML terminal myeloid differentiation.
(A) Schematic representation of EML cell line differentiation. The differentiation steps
performed in this experiment are shown in red. (B-E) qRT-PCR analysis of the mRNA
levels of: the stem cell marker c-kit (B), the differentiation markers Mac-1 and C/EBPε (C
& D respectively) , and Spy1 (E). All data are normalized to GAPDH endogenous control
and data are presented as relative quantification (RQ) on a logarithmic scale (log 10). Error
bars represent standard error of the mean of four independent experiments each run in
triplicate. Statistical analysis was assessed by the Student’s paired t-test (*p<0.001,
**p<0.05).
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V.

Leukemia Cell Growth Decreases in the Absence of Spy1
To study the role of Spy1 in leukemic stem cell populations, a human acute

promyelocytic cell line was chosen as a representative case of AML. HL-60 cells were
infected with lenti-virus to express pLKO-shSpy1 or with pLKO-shScrambled (pLKO) as
a control. qRT-PCR analysis was used to confirm the knock-down of Spy1; results
demonstrate approximately an 8 fold decrease in the expression of Spy1 in cells infected
with pLKO-shSpy1 compared to control pLKO cells (Figure 7A). Cells successfully
expressing pLKO and pLKO-shSpy1 were selected by growth media containing
puromycin. After 72 hours of selection, 100% of wildtype HL-60 cells were dead, while
100% of pLKO and approximately 80% of pLKO-shSpy1 cells were alive, indicating
they were successfully infected (Figure 7B-G). To assess the effect Spy1 depletion would
have on HL-60 cell growth, 100,000 cells were seeded in 6 well plates for each construct
and cell number was assessed every 24 hours using Trypan Blue Exclusion and cell
counts performed in triplicate. Results indicate that HL-60 cells exhibiting Spy1 knockdown grow more slowly than both pLKO control and wildtype cells at all time points
(Figure 8). After 72 hours of growth pLKO-shSpy1 cells have multiplied to produce
approximately 3.5 x 105 cells, whereas pLKO control cells have nearly double the cell
number (6 x 105 cells). Therefore, it is evident that HL-60 cells grow significantly slower
when Spy1 is depleted. These results were found to be statistically significant.

VI.

Expression of LSC Genes Decreases in the Absence of Spy1
CLL-1 and CD33 are both known to be highly expressed on leukemia cells in

patients with AML, but not on normal HSCs or non-myeloid cells66,68,70,88. In addition,
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Figure 7. Successful shRNA-mediated knock-down of Spy1 in HL-60 cells. HL-60
cells were infected with lentivirus carrying shRNA against Spy1 (pLKO-shSpy1) or a
scrambled control (pLKO). (A) qRT-PCR was used to assess knock-down efficiency. Data
is normalized to GAPDH andpresented as relative quantification (RQ) on a logarithmic
scale (log10). (B-G) Microscopy images of cells treated with Puromycin. (B, D, and F)
Total magnification of 100x.(C, E, and G) Total magnification of 200x.
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Figure 8. Spy1 knock-down slows HL-60 cell growth. Trypan blue exclusion assay was
performed to assess cell proliferation of HL-60 cells successfully infected with shRNA
against Spy1(pLKO-shSpy1) or scrambled control (pLKO). over a period of 72 hours.
Error bars represent the standard error of the mean viable cell number of three independent experiments each counted in triplicate. Statistical analysis using a Student’s paired ttest was performed to compare growth of pLKO to pLKO-shSpy1 cells (#p<0.001) and to
wildtype cells (*p<0.001, **p<0.005) at all time points.
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CLL-1 and CD33 have been previously studied as potential LSC targets in clinical trials
for treatment of human AML66-67,69. Following selection in puromycin, cells exhibiting
successful knock-down of Spy1 were analysed by qRT-PCR for expression of both CLL1 and CD33. Results indicate that both CLL-1 and CD33 levels are decreased in HL-60
cells expressing shSpy1 when compared to control pLKO cells (Figure 9). More
specifically, an approximate 3 fold decrease in the expression levels of CLL-1 and an
approximate 4 fold decrease in the expression levels of CD33 were observed. These
results indicate a potential role for Spy1 in promoting formation of LSC populations in
AML.

VII.

Spy1 Expression Increases During HL-60 Differentiation
To examine whether Spy1 levels may be altered by current therapeutic regimens

for AML, HL-60 cells were treated with atRA. Specifically, HL-60 cells were cultured in
media containing atRA for 5 days to allow for granulocytic differentiation or in media
containing 0.1% ethanol as a vehicle control. Cells were analysed using qRT-PCR for
expression of the human myeloid cell marker Mac-1 and for Spy1 at 3 days and 5 days
after the addition of atRA (Figure 10). Preliminary results demonstrate that Mac-1
expression levels increase as HL-60 cells differentiate, demonstrating an approximate 5.6
fold increase in expression over vehicle control cells by 5 days differentiation. Spy1 gene
expression also increased as HL-60 cells differentiated, demonstrating approximate 5 fold
and 16 fold increases in expression over cells treated with a vehicle control at 3 and 5
days atRA differentiation, respectively. Interestingly, this result is consistent with the
increase of Spy1 observed during atRA-induced terminal differentiation of EML cells.
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Relative Quantification Vs
GAPDH (log 10)
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Figure 9. Expression of LSC gene decreases in the absence of Spy1. Cells successfully
infected with either pLKO-shScrambled (pLKO) or pLKO-shSpy1 constructs were collected and analyzed for expression of known leukemic stem cell markers for acute
myelogenous leukemia. qRT-PCR was used to analyze mRNAlevels of CLL-1 and CD33.
Data was normalized to GAPDH and shown as relative quantification (RQ) on a logarithmic scale (log10). Error bars represent standard error of the mean of two independent
experiments.
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Figure 10. Spy1 expression increases during HL-60 cell differentiation. HL-60 cells
were stimulated to differentiate into terminal granulocytes using atRA. Cells treated with
a vehicle control (EtOH) are also shown. qRT-PCR analysis of Spy1 and of the differentiation marker Mac-1 show mRNA levels at 3 and 5 days differentiation. Data is normalized to GAPDH as an internal control and all data is represented as relative quantification
(RQ) on a logarithmic scale (log 10). Error bars represent the standard error of the mean of
three replicates of the same sample.
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VIII. Spy1 Protein is Significantly Elevated in Myelomas
To examine levels of Spy1 in a more differentiated blood malignancy, tissue
microarray analysis of human bone marrow-derived myeloma tumours was performed.
Specifically, Spy1 protein levels were examined in a variety of human myeloma samples
relative to levels in normal bone marrow. Paraffin-embedded tissues were stained with
anti-Spy1 antibody followed by Alexa488 fluorescent conjugated secondary antibody and
a nuclear control, TOTO-3. Results indicate that Spy1 protein is expressed in normal
human bone marrow and that this expression is significantly elevated in all of the tumour
samples examined to date (Figure 11). For example, Spy1 protein was expressed at levels
more than ten times as great as those observed in normal marrow (Figure 11; Myeloma of
the Vertebrae). Spy1 protein was increased to the least extent in Ewing’s sarcoma, but
even this expression was three times that of normal marrow samples (Figure 11).
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Figure 11. Spy1 protein is significantly elevated in multiple myelomas. Levels of Spy1
protein relative to a nuclear control stain, TOTO-3 are graphed. Tissues are representative
of four different types of multiple myeloma (n=16) (myeloma of the vertebrae, plasma
cell myeloma of the pubis, Ewing’s sarcoma, and myeloma of the neck) and normal bone
marrow tissue (n=8). Samples were obtained from human patients ranging in age from
10-57 years. Error bars represent the standard error of the mean. Statistical significance
was assessed using a student’s paired t-test in Statistica software (*p=0.001, **p=0.0003,
***p=0.00001)
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DISCUSSION
Collectively blood malignancies are the 4th most common cancer diagnosed in
both men and women worldwide1. Despite overall drops in mortality due to advances in
treatment and earlier diagnosis, leukemias still have a poor prognosis with an overall five
year survival rate of only 51%1. Blood malignancies represent a diverse group of cancers
with many genetic backgrounds, not all of which have been resolved to date. The findings
presented in this study have demonstrated involvement of the novel cell cycle regulator,
Spy1, in normal hematopoietic cell development and suggest implications for Spy1 in the
development of LSCs.
To determine whether Spy1 protein was expressed in tissues known to play
important roles in the hematopoietic system, tissue microarray analysis was performed. It
was found that Spy1 was expressed, at the protein level, rather ubiquitously across many
human fetal tissues. Notably, Spy1 protein was found to be expressed in fetal tissues
known to support hematopoietic cell development including the spleen, thymus, and liver.
This is consistent with previous work which demonstrated Spy1 expression in many
human tissues including the liver and thymus76. Of the tissues examined in this study,
Spy1 protein levels were greatest in the liver. The liver plays a very prominent role in
development of the hematopoietic system by supporting hematopoiesis for a large portion
of fetal development37,39,41. It is notable that Spy1 has been found to be involved in
hepatocellular carcinoma89; hence, whether expression is occurring in the hematopoietic
cells or early hepatic cells from these data is not known.
These results were further supported by western blot analysis of murine spleen,
thymus, and liver tissues where Spy1 protein was found to be expressed at 7 and 21 days
post-natal development. Consistent with the tissue microarray analysis, Spy1 was
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expressed to the greatest extent in the liver. The murine liver has been shown to support
HSC production and development for a short period of time post-natally39 and HSCs have
recently been identified in the adult mammalian liver41,90. Moreover, the presence of
hematopoietic progenitors capable of forming hematopoietic colonies in vitro has been
observed in many murine adult organs including the liver and the spleen90-91. Therefore,
this result provides further evidence that Spy1 is expressed in tissues important in early
hematopoietic development. Furthermore, densitometry analysis shows that Spy1 protein
expression decreased by day 21 in all tissues examined. The proportion of HSCs in
hematopoietic tissues is known to be the greatest in younger mammals due to a
developmental need34; thus, the decrease in Spy1 protein levels observed in older murine
samples may be explained by a decrease in the proportion of early stem and progenitor
cells in these tissues. However, due to the many cell types present in each of these tissues,
future steps should involve cell sorting in order to draw any direct conclusions between
Spy1 and HSC development in these tissues.
To further clarify a role for Spy1 in hematopoietic cell development, murine bone
marrow cells capable of erythroid, myeloid, and lymphoid (EML) differentiation in
response to different growth factors in vitro were utilized30,86. EML cells are
representative of the MPP population in hematopoietic development expressing the cell
surface markers c-kit, Sca-1, and some early lineage progenitor markers30. EML cells
have previously been immortalized by the expression of a dominant negative retinoic acid
receptor; this induces a block in EML myeloid differentiation that can be overcome with
very high concentrations of all-trans retinoic acid30. For the purposes of this study, EML
cells were induced to differentiate down the myeloid pathway by the addition of IL-3 and
atRA to generate the more committed myeloid progenitor cells, termed GMPs. Results
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show a significant decrease in Spy1 gene expression during the initial stages of EML
myeloid differentiation, demonstrating that Spy1 levels correlate with stages of
development focused on maintaining the early hematopoietic stem and progenitor cell
populations. This is consistent with previous work in our lab showing that Spy1 levels
correlate with its ability to regulate stemness decisions in both the breast and the
brain84,92. Future experiments in which Spy1 levels are manipulated prior to
differentiation will be necessary to further substantiate the functional importance of this
expression pattern and provide direct evidence that Spy1 plays a role in directing HSC or
MPP fate.
As previously mentioned, EML cells are known to be a heterogeneous population
of MPP cells expressing early stem cell genes such as c-kit and Sca-1, but also expressing
markers for early lineage progenitor cells30. Furthermore, EML cells contain both a
CD34+ and CD34- population of cells with different capacities to proliferate and
differentiate86. To determine if Spy1 is differentially expressed in certain populations of
the HSC compartment, EML cells were subject to immunomagnetic sorting to isolate
CD34+ and CD34- populations. Results demonstrate an approximate 50 fold increase in
Spy1 gene expression levels in the CD34+ EML population in comparison to both the
CD34- and the heterogeneous EML populations. This finding further demonstrates that
Spy1 expression correlates with the stages of hematopoietic development involving the
early CD34+ stem and MPP cells. Differential expression of CD34 in the murine
hematopoietic stem cell compartment mirrors the proliferative status of the cell
populations. Relatively quiescent LT-HSCs residing in the bone marrow niche are CD34and capable of long-term engraftment25-26,28,93. In contrast, ST-HSCs and MPPs have
transient engraftment ability, can be mobilized from the marrow, and are CD34+ 25-26,28,93.
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Despite these established correlative patterns, it is notable that differences in cell surface
protein expression have not been definitively linked as playing a causative role in the
functional differences between ST-HSCs and MPPs25-26,52,87,94. Spy1 is expressed to a
greater extent in the ST-HSCs and MPP cells and, therefore, Spy1 may be important in
fate decisions of these cells, however, this functional role needs to be directly assessed.
EML-derived GMP cells are dependent on GM-CSF for survival and can
spontaneously produce mature monocytes and macrophages. However, EML-derived
GMP cells display a defect in terminal granulocyte differentiation that can be overcome
with high concentrations of atRA30. To determine how Spy1 levels correlate with these
later stages of development, EML-derived GMP cells were induced to terminal
differentiation with GM-CSF and atRA. Control cells were grown in GM-CSF containing
medium. Interestingly, Spy1 mRNA levels were found to be elevated during the terminal
differentiation of EML cells, although changes in Spy1 levels were not significantly
greater than those observed in control cells. This may be due to the fact that EML-derived
GMPs are capable of spontaneously differentiating down the monocytic pathway;
therefore, differentiated cells of the monocyte lineage are likely present in the control cell
populations as indicated by the increases in Mac-1 and C/EBPε in these cells.
Although LT-HSCs and ST-HSCs have the highest capacity for self-renewal of all
hematopoietic cells, it has been discovered that MPPs, early and late lineage progenitor
cells, and even some mature blood cells maintain a proliferative index due to the high
turnover of blood cells95-96. Spy1 has been shown to be necessary for proliferation in a
variety of mammalian cell types76,82,84,92; therefore, perhaps Spy1 is elevated during the
differentiation of GMP cells to aid in proliferation of lineage progenitors and mature
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blood cells lower in the hierarchy. Alternatively, since Spy1 levels were only analysed at
the mRNA level, it is possible that Spy1 protein continues to decrease during GMP
differentiation, but that this is regulated at the translational or post-translational level.
Overall, this result may suggest broader implications for Spy1 in hematopoietic
development as it indicates a potential need for Spy1 in later stages of blood cell
differentiation.
Collectively, these in vitro experiments indicate that Spy1 expression correlates
with proliferative stages of myeloid development including the early stem and MPP
stages; therefore, subsequent experiments aimed to elucidate a role for Spy1 in AMLs
known to have LSC populations. HL-60 cells are human leukocytes consisting primarily
of neutrophilic promyelocytes taken from a patient with acute promyelocytic leukemia 94.
HL-60 cells were subjected to shRNA-mediated knock-down of Spy1 and effects on
growth were assessed using trypan blue exclusion and cell counts. It was observed that
HL-60 cells grew more slowly in the absence of Spy1 in comparison to both control
pLKO cells and wildtype HL-60 cells. This demonstrates that Spy1 plays an important
role in promoting cell growth and proliferation in this representative case of AML. These
results are consistent with previous data demonstrating a proliferative role for Spy1 in
mammalian cells76,82,84,97. Further exploration of these effects in a wide panel of AML cell
lines is needed.
Furthermore, HL-60 cells have been found to express high levels of the LSC
specific markers CLL-169 and CD3366. CLL-1 and CD33 have been extensively studied
and identified as potential LSC targets important in drug development and clinical trials
for the treatment of human AML66-67,69. Interestingly, when Spy1 was depleted using
shRNA in HL-60 cells, gene expression levels of both CLL-1 and CD33 decreased as
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assessed by qRT-PCR. This finding indicates a role for Spy1 in promoting the expression
of known LSC markers. Taken together, these results suggest a role for Spy1 in
promoting formation of LSC populations in this representative case of AML. This is
consistent with previous work from our lab and others demonstrating the involvement of
Spy1 in aggressive forms of breast and brain cancer and that Spy1 can promote the
expression of CSC markers important in driving tumour formation84,92,99-100. Future
experiments utilizing sorted CLL-1+ and CD33+ HL-60 cell populations are necessary to
accurately examine the effects of Spy1 knock-down on growth and proliferation of the
LSC compartment of HL-60 cells.
To address whether Spy1 levels are altered during therapeutic treatment of AML,
HL-60 cells were differentiated with atRA to mimic current treatment of acute
promyelocytic leukemia in the clinic. Promyelocytic leukemia is characterized by an
accumulation of promyelocytes in the bone marrow that are unable to complete
granulocytic differentiation8; treatment with atRA has seen much success clinically5-8,
however, cases of atRA resistant myelocytic leukemia have been reported101. As
previously observed, knock-down of Spy1 has effects on both leukemic cell growth and
LSC marker expression in this cell line. Therefore, it was my hypothesis that knock-down
of Spy1 might sensitize HL-60 cells to differentiation treatment with atRA. Surprisingly,
initial experiments examining endogenous levels of Spy1 during HL-60 atRA
differentiation showed an increase in Spy1 gene expression as cells became mature
granulocytes. Although this result is not consistent with the hypothesis for this
experiment, it is similar to the observations made during atRA induced terminal EML
maturation and may be explained by the proliferative potential maintained by late lineage
progenitors and mature blood cells95-96. Furthermore, it is important to note that Spy1
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levels were only examined at the mRNA level; protein analysis should be completed
before drawing final conclusions as it is possible that Spy1 is being regulated differently
at the translational level. Furthermore, functional effects of the knockdown of Spy1 on
success of treatment will require assays measuring overall cell growth properties
following treatment, including clonal assays to measure the effects on the LSC
population.
Lastly, tissue microarray analysis was performed to analyse protein expression of
Spy1 in human blood malignancies. Due to the endogenous expression of Spy1 observed
in late stage hematopoietic cells, a more differentiated blood malignancy, multiple
myeloma, was analyzed for expression of Spy1. Multiple myeloma is a plasma cell
malignancy affecting B lymphocyte development within the hematopoietic system49.
Results demonstrate that Spy1 protein is expressed in normal bone marrow, but that this
expression is significantly elevated in all of the myeloma tumours examined. This finding
implies that Spy1 may be important in myeloma and warrants further investigation into a
role for Spy1 in myelomas. Interestingly, this result suggests a link to Spy1 in a more
differentiated cancer in contrast to previous work from our lab showing implications for
Spy1 in aggressive breast and brain cancers of a stem cell origin84,92. This may be
explained by the fact that mature blood cells of the B cell lineage are highly proliferative
and can undergo clonal expansion during immune reactions34,96. Future directions may
aim to examine a role for Spy1 in EML B Cell differentiation decisions.
In summary, this study has demonstrated that Spy1 is expressed in mammalian
sites important to both murine and human hematopoiesis. Taken together, the decrease in
Spy1 expression during in vitro differentiation of EMLs and the high expression of Spy1
in CD34+ EML populations demonstrate that Spy1 is endogenously expressed within the
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ST-HSC and MPP compartment of the hematopoietic hierarchy. However, findings also
indentified Spy1 to be expressed in more mature hematopoietic cells. Collectively, these
in vitro experiments demonstrate a correlation between Spy1 expression and proliferative
stages of the hematopoietic hierarchy. Furthermore, these findings identify Spy1 as
important in promoting development of LSCs in one subtype of AML and it was revealed
that Spy1 is significantly elevated in a variety of human myelomas. Overall, this study
demonstrates that Spy1 may have broader implications in blood malignancies than the
previously identified role in some types of lymphoma85. These findings may have
implications into the future treatment of different blood malignancies.
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Appendix A
Gene Manipulation in EML Cells
This appendix reviews in detail the many different techniques attempted for both
transfection of plasmid DNA and infection using lenti-virus. In all cases, successful
transfection was assessed using a GFP reporter and light microscopy.

I Transfections
Transfections with polyethylenimine (PEI)
EML cells were seeded in 12 well plates at densities of 0.5 x 105 cells/mL, 1.0 x 105
cells/mL, and 2.0 x 105 cells/mL in serum-free media on the day of transfection. Plasmid
DNA for both the pEIZ control and pEIZ-Spy1 were diluted at a ratio of 1:10 in 150mM
NaCl. 1 µg plasmid DNA was then mixed with 5 µL of 10 mg/mL polyethylenimine
(PEI) in eppendorf tubes. This mixture was allowed to incubate at room temperature for
10 minutes prior to addition to cells. The plate was centrifuged for 5 minutes at 500 x g
and 4ºC. Following this centrifugation, media was replaced with serum-free media either
immediately or after approximately 16 hours.

Transfections with JetPrime Reagent
EML cells grown to approximately 75% confluency in 5 mL of complete growth media in
6 cm plates were transfected with GFP plasmid DNA using Jet Prime Reagent (VWR
CA89129-922) and following the manufacturer’s protocol. Briefly, plasmid DNA was
added to Jet Prime buffer in an eppendorf tube and vortexed prior to the addition of Jet
Prime Reagent. Following an incubation period of 10 minutes at room temperature,
plasmid DNA, Jet Prime Reagent, and buffer mixture was added to cells. Different ratios
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of plasmid DNA to Jet Prime Reagent and buffer can be found in table 3. Each
transfection was performed in duplicate so that transfection times of both 4 hours and 20
hours could be attempted.

Table 3. EML Transfection with JetPrime, Conditions
GFP
Plasmid Amount JetPrime
DNA (µg)
Reagent (µL)
Transfection 1
1.0
2
Transfection 2
2.0
3
Transfection 3
4.0
4

Amount Buffer
(µL)
100
200
200

II Infections with Lenti-Virus
Lenti-viral Infection
5,000, 10,000, 25,000 or 50,000 EML cells were seeded in 96 well plates in serum-free
and antibiotic-free media on the day of infection. Polybrene was added to media at final
concentrations ranging from 1 µg/mL to 8 µg/mL. In some instances lenti-virus
containing either the pEIZ control vector, pEIZ-Spy1, pLB-shScrambled, and pLBshSpy1were added immediately after the addition of polybrene. In other instances, cells
were allowed to incubate in media-containing polybrene for 20 to 30 minutes prior to the
addition of virus. Viral titres for all constructs were 107 TU/mL and different MOIs
ranging from 0.1 to 10 were attempted. EML cells were allowed to incubate with virus for
a minimum of 6 hours to a maximum of 24 hours. Upon removal of virus-containing
media, complete growth media was added.

Lenti-viral Infection – Spinoculation
50,000 EML cells were seeded in 96 well plates in serum-free media containing 4 to 8
µg/mL polybrene. After the addition of lenti-virus containing pEIZ control and pEIZ-
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Spy1, plates were subject to centrifugation at either 1500 rpm or 800 x g for 10 to 30
minutes at 32ºC. Following centrifugation, media was then replaced with complete
growth media. Alternatively, plates were allowed to incubate for a minimum of 6 hours
and a maximum of 24 hours before the removal of virus. MOI ranged from 1 to 5.

Lenti-viral Infection with Magnetic Beads
50,000 EML cells were seeded in 96 well plates in serum-free media containing 4 µg/mL
polybrene for infection with pEIZ control and pEIZ-Spy1. A mixture of magnetic beads
and virus was prepared at a ratio of 1 µL to 10 µL, respectively, and allowed to incubate
on ice for 30 minutes. During this incubation, bead-virus mixtures were vortexed every 5
minutes. Prior to the addition of the bead-virus mixture, plates were centrifuged for 5
minutes at 1500 rpm. Plates were then placed on a magnet and allowed to incubate for 20
minutes in a 37ºC humidified incubator. Virus-containing media was replaced with
complete growth media approximately 16 hours later.
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